Oral medicine for eliminating pyloric spirillar bacilli
Patent Information
- Authority / Receiving Office
- CN Β· China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- ιζ₯ε
- Publication Date
- 2005-01-05
- Estimated Expiration
- Not applicable Β· inactive patent
Abstract
Description
technical field
[0001] The invention relates to an oral pharmaceutical preparation for treating Helicobacter pylori infection. Background technique
[0002] Helicobacter pylori (HP for short) is the main pathogenic factor of chronic gastritis, is highly related to peptic ulcer, and is a risk factor of gastric cancer. A large number of studies have shown that killing HP can treat chronic gastritis, accelerate ulcer healing, reduce ulcer recurrence, and reduce gastric cancer. Therefore, scholars at home and abroad have extensively discussed the methods of eradicating HP. Although HP is sensitive to many antibiotics in vitro, the eradication rate of HP with monotherapy is not high (only 15%-20%), and it is prone to recurrence and drug resistance. Therefore, both at home and abroad, two or more than two kinds of drugs are usually combined to treat HP.
[0003] Since the Ninth World Gastrointestinal Congress recommended the first triple drug regimen to eradicate HP in 1990, ma...